- Conditions
- COVID-19, Immunosuppression, Vaccine Response Impaired
- Interventions
- Reduction in antimetabolite immunosuppression
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 147
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
- Interventions
- COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
- Biological · Other
- Lead sponsor
- GeoVax, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- Duarte, California • Baltimore, Maryland • Worcester, Massachusetts + 3 more
- Conditions
- COVID-19, COVID-19 Immunisation
- Interventions
- mRNA-1273
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Decatur, Georgia • Bethesda, Maryland • Seattle, Washington
- Conditions
- COVID-19
- Interventions
- Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine, BNT162b2 BA.4/5 bivalent, XBB.1.5-adapted vaccinated
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
- Conditions
- SARS CoV 2 Infection, COVID-19
- Interventions
- Pfizer/BioNTech (BNT162b2), Moderna
- Biological
- Lead sponsor
- DHR Health Institute for Research and Development
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Brownsville, Texas • Edinburg, Texas • Rio Grande City, Texas
- Conditions
- COVID-19
- Interventions
- SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4, SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more
- Conditions
- Papillomavirus Infections, Coronavirus Disease (COVID-19)
- Interventions
- 9vHPV Vaccine, mRNA-1273 Vaccine
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 9 Years to 11 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more
- Conditions
- COVID-19
- Interventions
- Nuvaxovid (NVX-CoV2705), mNEXSPIKE mRNA-1283
- Drug
- Lead sponsor
- Marcel Curlin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- SARS-CoV-2
- Interventions
- Not listed
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 50,000,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Trust
- Interventions
- RNA vaccine, 20% adoption rate, 40% adoption rate, 60% adoption rate, 80% adoption rate, Conventional vaccine, 0% adoption rate
- Other
- Lead sponsor
- National University of Singapore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35,180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- San Mateo, California
- Conditions
- Vaccination Refusal, COVID-19 Pandemic
- Interventions
- Doctor Videos, Sharing Videos, Sharing Videos (Influencers), Vaccine Ambassador, Video framing, Video order
- Behavioral
- Lead sponsor
- Massachusetts Institute of Technology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273, mRNA-1283, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 30,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 150
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more
- Conditions
- Multiple Sclerosis
- Interventions
- Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
- Other
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- SARS-CoV2, COVID-19
- Interventions
- VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
- Biological
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 145
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more
- Conditions
- COVID-19
- Interventions
- Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA, SARS-CoV-2 mRNA Dose 1, SARS-CoV-2 mRNA Dose 2, Licensed Flu Seasonal, Licensed COVID-19 mRNA, Placebo
- Combination Product · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 9
- States / cities
- Anniston, Alabama • Rolling Hills Estates, California • Hialeah, Florida + 5 more
- Conditions
- COVID-19
- Interventions
- VXA-CoV2-1.1-S, Placebo Tablets
- Drug · Other
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Long Beach, California • Wichita, Kansas • Cleveland, Ohio + 1 more
- Conditions
- Multiple Sclerosis
- Interventions
- SARS-COV-2 mRNA Vaccine
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Denver, Colorado • New York, New York
- Conditions
- Pneumococcal Infection
- Interventions
- V110, V114, mRNA-1273, Placebo for V110, Placebo for V114
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 42
- States / cities
- North Hollywood, California • Northridge, California • Paramount, California + 38 more
- Conditions
- COVID-19
- Interventions
- CVXGA (CVXGA50), COMIRNATY®
- Biological
- Lead sponsor
- CyanVac LLC
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 432 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 55
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Chula Vista, California + 44 more
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1283, mRNA-1283.211, mRNA-1273, mRNA-1283.529
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Hollywood, Florida • Sunrise, Florida + 13 more
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,051 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 37
- States / cities
- Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more
- Conditions
- SARS-CoV-2, Influenza
- Interventions
- mRNA-1073, mRNA-1010, mRNA-1273, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 14
- States / cities
- Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more
- Conditions
- Lung Transplant Recipient, SARS-CoV-2, Immunosuppression
- Interventions
- mRNA-1273 (Moderna COVID-19 vaccine)
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California